Tumor bioengineering using a transglutaminase crosslinked hydrogel.
Development of a physiologically relevant 3D model system for cancer research and drug development is a current challenge. We have adopted a 3D culture system based on a transglutaminase-crosslinked gelatin gel (Col-Tgel) to mimic the tumor 3D microenvironment. The system has several unique advantag...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4136878?pdf=render |
id |
doaj-194be2ca2cf04ec5bee4c41892144ca7 |
---|---|
record_format |
Article |
spelling |
doaj-194be2ca2cf04ec5bee4c41892144ca72020-11-25T01:44:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10561610.1371/journal.pone.0105616Tumor bioengineering using a transglutaminase crosslinked hydrogel.Josephine Y FangShih-Jye TanZhi YangCharisse TayagBo HanDevelopment of a physiologically relevant 3D model system for cancer research and drug development is a current challenge. We have adopted a 3D culture system based on a transglutaminase-crosslinked gelatin gel (Col-Tgel) to mimic the tumor 3D microenvironment. The system has several unique advantages over other alternatives including presenting cell-matrix interaction sites from collagen-derived peptides, geometry-initiated multicellular tumor spheroids, and metabolic gradients in the tumor microenvironment. Also it provides a controllable wide spectrum of gel stiffness for mechanical signals, and technical compatibility with imaging based screening due to its transparent properties. In addition, the Col-Tgel provides a cure-in-situ delivery vehicle for tumor xenograft formation in animals enhancing tumor cell uptake rate. Overall, this distinctive 3D system could offer a platform to more accurately mimic in vivo situations to study tumor formation and progression both in vitro and in vivo.http://europepmc.org/articles/PMC4136878?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Josephine Y Fang Shih-Jye Tan Zhi Yang Charisse Tayag Bo Han |
spellingShingle |
Josephine Y Fang Shih-Jye Tan Zhi Yang Charisse Tayag Bo Han Tumor bioengineering using a transglutaminase crosslinked hydrogel. PLoS ONE |
author_facet |
Josephine Y Fang Shih-Jye Tan Zhi Yang Charisse Tayag Bo Han |
author_sort |
Josephine Y Fang |
title |
Tumor bioengineering using a transglutaminase crosslinked hydrogel. |
title_short |
Tumor bioengineering using a transglutaminase crosslinked hydrogel. |
title_full |
Tumor bioengineering using a transglutaminase crosslinked hydrogel. |
title_fullStr |
Tumor bioengineering using a transglutaminase crosslinked hydrogel. |
title_full_unstemmed |
Tumor bioengineering using a transglutaminase crosslinked hydrogel. |
title_sort |
tumor bioengineering using a transglutaminase crosslinked hydrogel. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Development of a physiologically relevant 3D model system for cancer research and drug development is a current challenge. We have adopted a 3D culture system based on a transglutaminase-crosslinked gelatin gel (Col-Tgel) to mimic the tumor 3D microenvironment. The system has several unique advantages over other alternatives including presenting cell-matrix interaction sites from collagen-derived peptides, geometry-initiated multicellular tumor spheroids, and metabolic gradients in the tumor microenvironment. Also it provides a controllable wide spectrum of gel stiffness for mechanical signals, and technical compatibility with imaging based screening due to its transparent properties. In addition, the Col-Tgel provides a cure-in-situ delivery vehicle for tumor xenograft formation in animals enhancing tumor cell uptake rate. Overall, this distinctive 3D system could offer a platform to more accurately mimic in vivo situations to study tumor formation and progression both in vitro and in vivo. |
url |
http://europepmc.org/articles/PMC4136878?pdf=render |
work_keys_str_mv |
AT josephineyfang tumorbioengineeringusingatransglutaminasecrosslinkedhydrogel AT shihjyetan tumorbioengineeringusingatransglutaminasecrosslinkedhydrogel AT zhiyang tumorbioengineeringusingatransglutaminasecrosslinkedhydrogel AT charissetayag tumorbioengineeringusingatransglutaminasecrosslinkedhydrogel AT bohan tumorbioengineeringusingatransglutaminasecrosslinkedhydrogel |
_version_ |
1725027219649069056 |